Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Angina pectoris

Antianginal therapy shows no long-term benefit for prophylaxis

    • Cardiology
    • Congress Reports
    • Pharmaceutical medicine
    • RX
    • Studies
  • 3 minute read

Angina may persist or recur despite successful revascularization with percutaneous coronary intervention. In these cases, antianginal treatment is supplemented. To demonstrate the effectiveness of this approach, a clinical trial was conducted to demonstrate the long-term potential benefit and safety of trimetazidine as add-on therapy. But it didn’t.

Patients who undergo successful percutaneous coronary intervention (PCI) for angina and non-ST-segment elevation acute coronary syndrome usually have good long-term outcomes with optimal medical therapy. However, recurrence of angina symptoms or cardiovascular events may still occur. This should prevent the additional administration of antianginal drugs. This procedure has so far been given a Class IIA recommendation in the European guidelines. Trimetazidine is an antianginal agent that improves energy metabolism of ischemic myocardium and may improve outcomes and symptoms in patients who have recently had PCI. The substance inhibits beta-oxidation of fatty acids and enhances glucose oxidation, which in sum reduces myocardial oxygen consumption.

In a randomized, double-blind, placebo-controlled, event-driven trial, 6007 patients at 365 centers in 27 countries who had successfully undergone PCI were studied over five years. Patients were between 21 and 85 years of age and had had either elective PCI for stable angina or urgent PCI for unstable angina or non-ST-segment elevation myocardial infarction (NSTEMI) less than 30 days before randomization. Randomized to receive either 35 mg trimetazidine or placebo twice daily.

The primary efficacy end point was a combination of cardiac death; hospitalization for a cardiac event; recurrence or persistence of angina requiring addition, change, or increase in dose of at least one antianginal drug; or recurrence or persistence of angina requiring coronary angiography.

Endpoint events very rare

The results show that there was no significant difference in incidence between the two groups. So, in the end, it didn’t matter whether the patients were treated with the active ingredient or placebo. The relative risk was 0.98 (95% CI 0.88-1.09; p=0.73) in the trimetazine group. This was true for patients who had received PCI for chronic angina as well as for patients after NSTEMI. In addition, endpoint events were quite rare at 25%. A look at the subgroups also revealed no differences. Patients in the verum arm did not have fewer symptoms, nor did they improve more frequently in angina classification by CCS. 1219 (40-9%) of 2983 patients in the trimetazidine group and 1230 (41-1%) of 2990 patients in the placebo group had serious treatment-related adverse events. However, long-term administration of trimetazidine was not associated with statistically significant safety concerns.

Results give pause for thought

It is difficult to fathom how the disappointing results came about. One possible reason could have been the already good treatment of those affected. Nearly all patients had received dual antiplatelet therapy and were taking statins. The use of other antianginal drugs was also the rule rather than the exception. 83% were taking beta blockers, 27% calcium channel blockers, 12% long-acting nitrates, and 22% other antianginal agents. Nevertheless, routine use of oral trimetazidine 35 mg twice daily for several years should be reconsidered. It does not appear to affect angina recurrence or outcome in patients receiving optimal medical therapy after successful PCI.

 

Further reading:

  • Ferrari R, et al: Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial. Lancet 2020, August 30. DOI: 10.1016/S0140-6736(20)31790-6.

 

CARDIOVASC 2020; 19(4): 24 (published 8/12/20, ahead of print).

Autoren
  • Leoni Burggraf
Publikation
  • CARDIOVASC
Related Topics
  • Angina pectoris
  • Trimetazidine
Previous Article
  • Germ cell tumors of the testis

Management of early stages: State of the art

  • Congress Reports
  • Oncology
  • RX
  • Urology
View Post
Next Article
  • Digital Health Technology

Artificial Intelligence and “Big Data” – also a trend in dermatology

  • Congress Reports
  • Dermatology and venereology
  • Prevention and health care
  • RX
View Post
You May Also Like
View Post
  • 6 min
  • Case Report

Breast cancer metastases in the bladder

    • Cases
    • Education
    • Gynecology
    • Oncology
    • RX
    • Urology
View Post
  • 11 min
  • Findings from the ALS Symposium 2024 in Montreal

Current and future approaches in the treatment of amyotrophic lateral sclerosis (ALS)

    • Congress Reports
    • Interviews
    • Neurology
    • RX
    • Studies
View Post
  • 8 min
  • Efficacy, mechanism of action and clinical effects

Garlic and high blood pressure

    • Cardiology
    • Education
    • General Internal Medicine
    • Pharmaceutical medicine
    • Phytotherapy
    • RX
    • Studies
View Post
  • 7 min
  • Moderate to severe chronic hand eczema

Delgocitinib cream – first topical pan-JAK inhibitor approved in Switzerland

    • Allergology and clinical immunology
    • Dermatology and venereology
    • Education
    • Infectiology
    • Market & Medicine
    • Pharmacology and toxicology
    • RX
View Post
  • 9 min
  • Wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CA)

Diagnosis at an early stage, prognostic classifications and outlook

    • Cardiology
    • Education
    • RX
    • Studies
View Post
  • 4 min
  • Case report: Drug-induced hepatitis

Rare side effect of tirzepatide therapy

    • Cases
    • Education
    • Endocrinology and Diabetology
    • Gastroenterology and Hepatology
    • Pharmacology and toxicology
    • RX
    • Studies
View Post
  • 4 min
  • Plea for sex-specific neurology

Migraine in men: underdiagnosed, underestimated, under-researched

    • Education
    • Neurology
    • RX
    • Studies
View Post
  • 4 min
  • Prurigo nodularis

Retrospective analyses of large data sets from everyday practice

    • Allergology and clinical immunology
    • Congress Reports
    • Dermatology and venereology
    • RX
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
  • Dermatology News

    Zum Thema
Top CME content
  • 1
    Patience, knowledge and persistence in therapy
  • 2
    Sarcopenia and malnutrition in the context of pneumological rehabilitation
  • 3
    Medical and psychosocial perspectives
  • 4
    New nomenclature for non-alcoholic fatty liver disease
  • 5
    Examinations and considerations before therapy

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.